ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Cervical Cancer

ASCO 2016 Genitourinary Cancers Symposium

Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium, held January 7–9 in San Francisco. We’ll bring you reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way genitourinary cancers are managed and treated.

Cervical Cancer

In this review, we will summarize clinical trials that have used various immunotherapeutic strategies, with a particular focus on recently emerging data for new agents and combinations.

Adolescent girls who live in predominantly Hispanic and high poverty communities are more likely to have had at least one HPV vaccine dose compared to girls in low poverty communities and those with different ethnic make up.

Small- and large-cell neuroendocrine tumors of the cervix are exceedingly rare and exceedingly aggressive.

A review by the European Medicines Agency shows that the HPV vaccine does not cause complex regional pain syndrome and postural orthostatic tachycardia syndrome.

In this interview we discuss the latest on HPV vaccines for cancer prevention and some of the struggles countries face in achieving widespread adoption.

An investigational vaccine has shown activity as a therapeutic treatment for high-grade pre-cancerous cervical lesions caused by the human papillomavirus.

Fertility preservation for patients diagnosed with early-stage cervical cancer is feasible and has gained acceptance within the gynecologic oncology community.

Pages

Subscribe to Cervical Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.